Related Experiment Video
Updated: Sep 9, 2025

Author Spotlight: Innovating Thiol Quantification and Biomarker Detection for Oxidative Stress Research
Published on: June 28, 2024
tRF-21LeuTAA Promotes Oxidative Stress by Altering Glutathione Metabolic Enzymes to Support Prostate Cancer
Xiaoyu Guo1, Jinjing Zhong1, Jingyu Qian1
1Department of Pathology, and Laboratory of Pathology, West China Hospital, and National Key Laboratory of Biotherapy, Sichuan University, Chengdu, China.
Abstract:
Transfer RNA-derived fragments (tRF) are a class of small noncoding RNAs that have recently been implicated in various physiologic and pathologic processes, including tumor development and progression. Identification of the roles of tRFs in cancer could provide insights into tumor biology and treatment strategies. In this study, we found that tRF-21LeuTAA (tRF-21) supported the progression of prostate cancer by regulating glutathione metabolic enzymes and promoting reactive oxygen species (ROS) accumulation. Nuclear tRF-21 upregulated leucyl aminopeptidase 3 (LAP3) by binding to its promoter and recruiting H3K27ac acetyltransferase P300 and transcription factor STAT1. The increased cystine-glycine dipeptidase activity of LAP3 led to increased degradation of the antioxidant glutathione. Alternatively, cytoplasmic tRF-21 suppressed glutathione S-transferase mu 3 by repressing its mRNA posttranscriptionally, which further elevated ROS by decreasing scavenger glutathione S-transferase activity. The accumulation of intracellular ROS downstream of tRF-21-mediated alterations in LAP3 and glutathione S-transferase mu 3 resulted in AKT activation. Overexpression of tRF-21 promoted the proliferation and migration of prostate cancer cells, formation of spheroids, and initiation and growth of tumors in a xenograft model. In patients, elevated tRF-21 and LAP3 levels were associated with unfavorable survival outcomes. The regulatory circuitry revealed in the present study may represent potential therapeutic targets for prostate cancer as well as various malignancies with tRF-21 overexpression.
Significance:
tRF-21 promotes tumor development by disrupting key metabolic, epigenetic, transcriptional, and post-transcriptional processes that converge on increased oxidative stress, suggesting that targeting this axis may benefit malignancies with elevated tRF-21.
Insights
Transfer RNA (tRNA)-derived fragments (tRFs), specifically tRF-21, promote prostate cancer by altering glutathione metabolism and increasing reactive oxygen species (ROS). Elevated tRF-21 and LAP3 indicate poor survival outcomes in patients.
Area of Science:
- Molecular Biology
- Cancer Research
- RNA Biology
Background:
- Transfer RNA (tRNA)-derived fragments (tRFs) are small non-coding RNAs involved in various cellular processes.
- tRFs have emerged as key regulators in tumor development and progression.
- Understanding tRF roles in cancer offers insights into tumor biology and therapeutic strategies.
Purpose of the Study:
- To investigate the role of tRF-21LeuTAA in prostate cancer progression.
- To elucidate the molecular mechanisms by which tRF-21LeuTAA influences cancer development.
- To identify potential therapeutic targets for prostate cancer based on tRF-21LeuTAA regulation.
Main Methods:
- Analysis of tRF-21LeuTAA function in prostate cancer cells and xenograft models.
- Investigation of tRF-21LeuTAA interactions with glutathione metabolic enzymes, LAP3, and GSTM3.
- Assessment of reactive oxygen species (ROS) accumulation and AKT activation.
- Correlation of tRF-21 and LAP3 levels with patient survival outcomes.
Main Results:
- tRF-21LeuTAA promotes prostate cancer progression by regulating glutathione metabolism and increasing ROS.
- Nuclear tRF-21LeuTAA upregulates LAP3, degrading glutathione; cytoplasmic tRF-21LeuTAA suppresses GSTM3, further increasing ROS.
- tRF-21LeuTAA overexpression enhances cancer cell proliferation, migration, spheroid formation, and tumor growth.
- Elevated tRF-21 and LAP3 levels in patients correlate with unfavorable survival.
Conclusions:
- tRF-21LeuTAA acts as a crucial oncogenic factor in prostate cancer through ROS accumulation.
- The identified regulatory network involving tRF-21LeuTAA, LAP3, and GSTM3 presents potential therapeutic targets.
- Targeting tRF-21 or its downstream effectors may offer new strategies for treating prostate cancer and other malignancies.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

